Supratentorial Neoplasms: Clinical Trials

13 trials for Supratentorial Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 active not recruiting, 2 terminated, 1 recruiting. 13 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 113Completed 7, Active not recruiting 2, Terminated 2, Recruiting 1, Unknown 1

Follow Supratentorial Neoplasms: new trials by email Literature Review of Supratentorial Neoplasms trials Research Report on Supratentorial Neoplasms

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
FET-PET/MRI - Pituitary Adenoma
Phase 1RecruitingMayo Clinic52026-01-082026-03-09
Opioid Free VS Opioid Anesthesia for Craniotomies
Opioid free anesthetics, Opioid Anesthetics - Supratentorial Neoplasms
Phase 1CompletedKasr El Aini Hospital602021-07-052021-10-19
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
Bevacizumab-IRDye800CW, Molecular Fluorescence Endoscopy platform - Pituitary Tumor, Pituitary Adenoma
Phase 1CompletedUniversity Medical Center Groningen202020-10-282023-04-14
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging, Blood and Urine samples - Brain Cancer, Pituitary Adenoma
Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center172018-03-072026-05-01
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
G207 - Supratentorial Neoplasms, Malignant, Malignant Glioma
Phase 1CompletedGregory K. Friedman, MD132016-05-012024-01-19
Intraoperative Imaging of Pituitary Adenomas by OTL
OTL38 - Neoplasms, Pituitary Neoplasms
Phase 1TerminatedUniversity of Pennsylvania332015-10-012019-08-06
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Photofrin (porfimer sodium) & photodynamic therapy. - Brain Tumor, Recurrent
Phase 1CompletedHarry T Whelan, MD52013-03-012019-02-25
Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT
18F-FDG - Pituitary Adenoma
Phase 1UnknownPeking Union Medical College Hospital1002013-02-012018-01-19
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Phase 1TerminatedNational Cancer Institute (NCI)1292010-03-012014-11-05
Fluorescence Guided Resection of Brain Tumors
5-aminolevulinic acid - Brain Tumors
Phase 1CompletedDavid W. Roberts1052007-05-012019-06-14
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
Lonafarnib, Temozolomide - Malignant Supratentorial Neoplasm, Recurrent Glioblastoma
Phase 1Active not recruitingM.D. Anderson Cancer Center342004-12-212024-10-17
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
entinostat - Cancer
Phase 1CompletedNational Institutes of Health Clinical Center (CC)752001-03-012012-03-15
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
yttrium Y 90-edotreotide - Brain and Central Nervous System Tumors, Breast Cancer
Phase 1CompletedNovartis Pharmaceuticals601998-01-012013-05-01

Narrower conditions

Pituitary Neoplasms (10)  ·  Brain Neoplasms (6)  ·  Astrocytoma (5)  ·  Oligodendroglioma (5)  ·  Ependymoma (4)  ·  Glioblastoma (4)  ·  Glioma (4)  ·  Medulloblastoma (4)  ·  Meningioma (4)  ·  Neoplasms (4)  ·  Neuroectodermal Tumors, Primitive (4)  ·  Burkitt Lymphoma (3)  ·  Choroid Plexus Neoplasms (3)  ·  Craniopharyngioma (3)  ·  Glioma, Subependymal (3)

Broader conditions

Brain Diseases (13)  ·  Central Nervous System Diseases (13)  ·  Neoplasms by Site (13)  ·  Nervous System Diseases (13)  ·  Nervous System Neoplasms (13)  ·  Central Nervous System Neoplasms (12)  ·  Endocrine Gland Neoplasms (10)  ·  Endocrine System Diseases (10)  ·  Hypothalamic Diseases (10)  ·  Hypothalamic Neoplasms (10)  ·  Pituitary Diseases (10)  ·  Neoplasms (9)  ·  Brain Neoplasms (7)  ·  Neoplasms by Histologic Type (7)

Interventions

2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  90Y-octreotide, DOTA-Tyr(3)- (1)  ·  Aminolevulinic Acid (1)  ·  Blood Specimen Collection (1)  ·  Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  Dihematoporphyrin Ether (1)  ·  Fluorodeoxyglucose F18 (1)  ·  Pafolacianine (1)  ·  Photochemotherapy (1)  ·  Temozolomide (1)  ·  entinostat (1)  ·  lonafarnib (1)

Sponsors

David W. Roberts (1)  ·  Gregory K. Friedman, MD (1)  ·  Harry T Whelan, MD (1)  ·  Kasr El Aini Hospital (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  Novartis Pharmaceuticals (1)  ·  Peking Union Medical College Hospital (1)  ·  University Medical Center Groningen (1)  ·  University of Pennsylvania (1)

Countries

United States (10)  ·  Canada (1)  ·  China (1)  ·  Egypt (1)  ·  Netherlands (1)

Top investigators

David W Roberts, MD (1)  ·  Gregory K Friedman, M.D. (1)  ·  Harry T Whelan, MD (1)  ·  Jeff Knipstein, MD (1)  ·  Keith Paulsen, PhD (1)  ·  Larry K. Kvols, MD (1)  ·  Najat Daw (1)  ·  Neetu Soni, MBBS, MD (1)  ·  Nelson Moss, MD (1)  ·  Rania S Fahmy (1)  ·  Shivaani Kummar, MD (1)  ·  Vinay Puduvalli (1)  ·  Zhaohui Zhu, M.D.,PhD (1)

Results publications

PMID 33838625, PMID 34620658, PMID 39390132

NIH funding

R01NS052274 (1), U01CA097452 (1)